Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

J. Li



Author of

  • +

    P2.01 - Advanced NSCLC (ID 618)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P2.01-025 - Evaluation of Calculating Carboplatin Dosage in Carboplatin–Pemetrexed Therapy in Chinese Patients with Advanced NSCLC (ID 8768)

      09:00 - 09:00  |  Author(s): J. Li

      • Abstract
      • Slides

      Background:
      We conducted a study to explore the application of carboplatin in carboplatin–pemetrexed therapy and determine the recommended dose of carboplatin in Chinese patients with chemo-naive advanced nonsquamous nonsmall-cell lung cancer (NSCLC).

      Method:
      From January 2014 to April 2016, 151 patients with chemo-naive NSCLC, who were treated with carboplatin plus pemetrexed (500 mg/m2), was conducted. The area under the curve (AUC) of carboplatin was back-calculated from actual dosages using the Calvert formula. Patients were divided into two groups according to an AUC ≥4 or an AUC <4, respectively. The primary efficacy endpoint were overall response rate (ORR) and disease control rate (DCR). Adverse events (AEs) were evaluated with NCI-CTCAE 3.0.

      Result:
      The median AUC of carboplatin was 4.0 (1.8-5.5). A total of 79 patients had an AUC ≥4 and 72 patients had an AUC <4. The ORR and DCR of all patients were 33.8% and 90.1%, respectively. The ORR and DCR were 35.4% and 86.1%, respectively, in the AUC ≥4 group, 31.9% and 94.4%, respectively, in the AUC <4 group. No difference was observed in ORR (p=0.650) and DCR (p=0.086) in the AUC ≥4 or AUC <4 group. Furthermore, no significant difference was observed in all grade or grade ≥3 AEs in the two groups.

      Conclusion:
      Our study suggested that compared to Western populations, the calculating dosages of carboplatin using the Calvert formula was common insufficient for Chinese populations, fortunately, therapeutic efficacy remained equally. In addition, it was not increased by maintaining the AUC of carboplatin at ≥4.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.